E
Marizyme, Inc.
MRZM
$0.0018
-$0.0482-96.40%
E
Sell
11/21/2023Downgrade
Marizyme, Inc. (MRZM) was downgraded to E+ from D- on 11/21/2023 due to a significant decline in the solvency index, growth index and total return index. Earnings per share declined from -$0.4764 to -$0.7083, the quick ratio declined from 0.02 to 0.01, and total revenue declined 1.73% from $184.7 to $181.5.
Marizyme, Inc. (MRZM) was downgraded to E+ from D- on 11/21/2023 due to a significant decline in the solvency index, growth index and total return index. Earnings per share declined from -$0.4764 to -$0.7083, the quick ratio declined from 0.02 to 0.01, and total revenue declined 1.73% from $184.7 to $181.5.
D
Sell
11/7/2023Upgraded
Marizyme, Inc. (MRZM) was upgraded to D- from E+ on 11/7/2023 due to an increase in the volatility index, total return index and growth index. Total revenue increased 43.18% from $129 to $184.7.
Marizyme, Inc. (MRZM) was upgraded to D- from E+ on 11/7/2023 due to an increase in the volatility index, total return index and growth index. Total revenue increased 43.18% from $129 to $184.7.
E
Sell
5/3/2023Downgrade
Marizyme, Inc. (MRZM) was downgraded to E+ from D- on 5/3/2023 due to a decline in the volatility index, growth index and total return index.
Marizyme, Inc. (MRZM) was downgraded to E+ from D- on 5/3/2023 due to a decline in the volatility index, growth index and total return index.
D
Sell
4/18/2023Upgraded
Marizyme, Inc. (MRZM) was upgraded to D- from E+ on 4/18/2023 due to an increase in the volatility index and valuation index.
Marizyme, Inc. (MRZM) was upgraded to D- from E+ on 4/18/2023 due to an increase in the volatility index and valuation index.
E
Sell
3/14/2023Downgrade
Marizyme, Inc. (MRZM) was downgraded to E+ from D- on 3/14/2023 due to a decline in the total return index and volatility index.
Marizyme, Inc. (MRZM) was downgraded to E+ from D- on 3/14/2023 due to a decline in the total return index and volatility index.
D
Sell
2/3/2023Downgrade
Marizyme, Inc. (MRZM) was downgraded to D- from D on 2/3/2023 due to a significant decline in the total return index, solvency index and volatility index. Debt to equity increased from 0.04 to 0.06, and the quick ratio declined from 1.41 to 0.78.
Marizyme, Inc. (MRZM) was downgraded to D- from D on 2/3/2023 due to a significant decline in the total return index, solvency index and volatility index. Debt to equity increased from 0.04 to 0.06, and the quick ratio declined from 1.41 to 0.78.
D
Sell
10/13/2022Downgrade
Marizyme, Inc. (MRZM) was downgraded to D from D+ on 10/13/2022 due to a decline in the total return index.
Marizyme, Inc. (MRZM) was downgraded to D from D+ on 10/13/2022 due to a decline in the total return index.
D
Sell
6/27/2022Upgraded
Marizyme, Inc. (MRZM) was upgraded to D+ from D on 6/27/2022 due to a significant increase in the total return index, solvency index and volatility index. The quick ratio increased from 1.32 to 1.93.
Marizyme, Inc. (MRZM) was upgraded to D+ from D on 6/27/2022 due to a significant increase in the total return index, solvency index and volatility index. The quick ratio increased from 1.32 to 1.93.
D
Sell
5/5/2022Upgraded
Marizyme, Inc. (MRZM) was upgraded to D from D- on 5/5/2022 due to an increase in the volatility index and total return index.
Marizyme, Inc. (MRZM) was upgraded to D from D- on 5/5/2022 due to an increase in the volatility index and total return index.
D
Sell
4/20/2022Downgrade
Marizyme, Inc. (MRZM) was downgraded to D- from D on 4/20/2022 due to a large decline in the solvency index, total return index and growth index. Total revenue declined 265.86% from $37.2 to -$61.7, earnings per share declined from -$0.0454 to -$0.1516, and EBIT declined 67.5% from -$1.76M to -$2.94M.
Marizyme, Inc. (MRZM) was downgraded to D- from D on 4/20/2022 due to a large decline in the solvency index, total return index and growth index. Total revenue declined 265.86% from $37.2 to -$61.7, earnings per share declined from -$0.0454 to -$0.1516, and EBIT declined 67.5% from -$1.76M to -$2.94M.
D
Sell
11/23/2021Upgraded
Marizyme, Inc. (MRZM) was upgraded to D from D- on 11/23/2021 due to an increase in the volatility index.
Marizyme, Inc. (MRZM) was upgraded to D from D- on 11/23/2021 due to an increase in the volatility index.
D
Sell
11/8/2021Downgrade
Marizyme, Inc. (MRZM) was downgraded to D- from D on 11/8/2021 due to a significant decline in the total return index, growth index and volatility index.
Marizyme, Inc. (MRZM) was downgraded to D- from D on 11/8/2021 due to a significant decline in the total return index, growth index and volatility index.
D
Sell
5/4/2020Downgrade
Marizyme, Inc. (MRZM) was downgraded to D from D+ on 5/4/2020 due to a major decline in the efficiency index and valuation index.
Marizyme, Inc. (MRZM) was downgraded to D from D+ on 5/4/2020 due to a major decline in the efficiency index and valuation index.
D
Sell
4/17/2020Upgraded
Marizyme, Inc. (MRZM) was upgraded to D+ from D on 4/17/2020 due to a noticeable increase in the total return index, growth index and volatility index. Operating cash flow increased 397.73% from -$4.4 to $13.1, earnings per share increased from -$0.0256 to -$0.0122, and EBIT increased 46.61% from -$507.6 to -$271.
Marizyme, Inc. (MRZM) was upgraded to D+ from D on 4/17/2020 due to a noticeable increase in the total return index, growth index and volatility index. Operating cash flow increased 397.73% from -$4.4 to $13.1, earnings per share increased from -$0.0256 to -$0.0122, and EBIT increased 46.61% from -$507.6 to -$271.
D
Sell
3/31/2020Downgrade
Marizyme, Inc. (MRZM) was downgraded to D from D+ on 3/31/2020 due to a noticeable decline in the total return index.
Marizyme, Inc. (MRZM) was downgraded to D from D+ on 3/31/2020 due to a noticeable decline in the total return index.
D
Sell
3/16/2020Upgraded
Marizyme, Inc. (MRZM) was upgraded to D+ from D on 3/16/2020 due to a noticeable increase in the total return index, efficiency index and valuation index. Total capital increased 0.48% from $28.4M to $28.53M.
Marizyme, Inc. (MRZM) was upgraded to D+ from D on 3/16/2020 due to a noticeable increase in the total return index, efficiency index and valuation index. Total capital increased 0.48% from $28.4M to $28.53M.
D
Sell
10/25/2018None
Marizyme, Inc. (MRZM) was downgraded to D from U on 10/25/2018.
Marizyme, Inc. (MRZM) was downgraded to D from U on 10/25/2018.
OTC PK
03/11/2025 3:10PM Eastern
Quotes delayed
